The Targeted Drug Delivery of Doxorubicin
W.M. Saltzman, T. Fahmy and P.M. Fong
Yale University, US
targeted drug delivery, chemotherapy, doxorubicin, controlled release, peg, toxicity
Carigent has developed a novel technology for attaching a high density of biological molecules to the surface of biodegradable, drug-loaded PLGA particles. These particles are characterized by a long-lasting presentation of the high density surface ligands. The combination of these factors position the Carigent technology as a premier reformulation apparatus for a large variety of drugs and target ligands. Because of this flexibility and ease of preparation this technology promises unprecedented effectiveness in a range of clinical therapeutic applications for cancer, cardiovascular, autoimmune and alloimmune disease.
An exciting aspect of Carigent’s technology is its versatility. Any drug, small or large molecule can be encapsulated inside of the particles while any desired ligand molecule can be attached to the surface. Carigent is currently focused on several products using this technology including a targeted version of doxorubicin for anti-cancer (non-hodgkins lymphoma) treatment. The doxorubicin re-formulation shows one example of the power of this technique; pre-clinical experimentation has shown that Carigent targeted doxorubicin is 100 times more powerful and with lower toxicitythan free doxorubicin.
This versatility will offer ample opportunity for corporate licensing and partnering with pharmaceutical and biotechnology companies for further generic drug reformulation.
Back to Program
Nanotech 2006 Conference Program Abstract